American Atomics Inc. (CSE:NUKE)

CTI BioPharma Income Statement

Financials in millions CAD. Fiscal year is September - August.

Fiscal Year	TTM	FY 2024	FY 2023
Period Ending	May 31, 2025	Aug 31, 2024	Aug 31, 2023
Selling, General & Admin	0.3	0.13	0.03
Operating Expenses	0.66	0.15	0.03
Operating Income	-0.66	-0.15	-0.03
Other Non Operating Income (Expenses)	-0.06	-0.02	-0
Pretax Income	-0.72	-0.17	-0.03
Net Income	-0.72	-0.17	-0.03
Net Income to Common	-0.72	-0.17	-0.03
Shares Outstanding (Basic)	23	17	4
Shares Outstanding (Diluted)	23	17	4
Shares Change (YoY)	47.44%	358.26%	-
EPS (Basic)	-0.03	-0.01	-0.01
EPS (Diluted)	-0.03	-0.01	-0.01
Free Cash Flow	-0.84	-0.2	-0.15
Free Cash Flow Per Share	-0.04	-0.01	-0.04
EBIT	-0.66	-0.15	-0.03

Source: S&P Global Market Intelligence. Standard template. Financial Sources.